Heparin-induced thrombocytopenia

Noah Berkowitz, Joshua Beckman, Mark J. Shumate, Nicolas Hougardy, Jean Pascal Machiels, Christophe Ravoet, Theodore E. Warkentin, Jack Hirsh, John G. Kelton

Research output: Contribution to journalLetterpeer-review

1 Scopus citations


To the Editor: We disagree that the study by Warkentin et al. (May 18 issue)1 identified a difference in outcome favoring the use of low-molecular-weight heparin. Their initial study of the identical patient population found no statistically significant difference in thrombotic events, incidence of venous thrombosis, episodes of major bleeding, or red-cell–transfusion requirements between the group given standard heparin and the group given low-molecular-weight heparin.2 From both studies (really the same study) one can conclude only that heparin-induced thrombocytopenia is a marker of thrombotic disease, because the authors do not demonstrate that thrombosis as a consequence of heparin-induced thrombocytopenia has.

Original languageEnglish (US)
Pages (from-to)1006-1007
Number of pages2
JournalNew England Journal of Medicine
Issue number15
StatePublished - Oct 12 1995
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Heparin-induced thrombocytopenia'. Together they form a unique fingerprint.

Cite this